Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

VALGANCICLOVIR CONTAINING IMPURITY T CRS (15 MG)

VALGANCICLOVIR CONTAINING IMPURITY T CRS (15 MG)

ND

DISCOVER
OXYTOCIN FOR NMR IDENTIFICATION CRS (5 MG)

OXYTOCIN FOR NMR IDENTIFICATION CRS (5 MG)

ND

DISCOVER
VALGANCICLOVIR HYDROCHLORIDE CRS (90 MG)

VALGANCICLOVIR HYDROCHLORIDE CRS (90 MG)

ND

DISCOVER
SAXAGLIPTIN IMPURITY MIXTURE CRS (0.004 MG)

SAXAGLIPTIN IMPURITY MIXTURE CRS (0.004 MG)

ND

DISCOVER
SAXAGLIPTIN FOR SYSTEM SUITABILITY CRS (1.082 MG)

SAXAGLIPTIN FOR SYSTEM SUITABILITY CRS (1.082 MG)

ND

DISCOVER
RIBOFLAVIN SODIUM PHOSPHATE FOR PEAK IDENTIFICATION CRS (15

RIBOFLAVIN SODIUM PHOSPHATE FOR PEAK IDENTIFICATION CRS (15

ND

DISCOVER
COLISTIN FOR SYSTEM SUITABILITY A CRS (10 MG)

COLISTIN FOR SYSTEM SUITABILITY A CRS (10 MG)

ND

DISCOVER
EPHEDRINE FOR ASSAY CRS - * DRUG PRECURSOR (160 MG)

EPHEDRINE FOR ASSAY CRS - * DRUG PRECURSOR (160 MG)

ND

DISCOVER
PROMAZINE IMPURITY B CRS (15 MG)

PROMAZINE IMPURITY B CRS (15 MG)

ND

DISCOVER
FELODIPINE FOR PEAK IDENTIFICATION CRS (15 MG)

FELODIPINE FOR PEAK IDENTIFICATION CRS (15 MG)

ND

DISCOVER
FLUNARIZINE FOR SYSTEM SUITABILITY CRS (20 MG)

FLUNARIZINE FOR SYSTEM SUITABILITY CRS (20 MG)

ND

DISCOVER
PROMAZINE IMPURITY C CRS (15 MG)

PROMAZINE IMPURITY C CRS (15 MG)

ND

DISCOVER